Skip to main content
main-content

Coronary artery disease

01-15-2021 | Empagliflozin | News

SGLT2 inhibition may reduce myocardial extracellular volume

Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.

06-24-2020 | Heart failure | Highlight | News

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

02-26-2020 | Coronary artery disease | Highlight | News

Urgent action needed to improve dysglycemia screening in patients with heart disease

More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

Related topics

Superior

Related

Image Credits